Xenon pauses Phase 3 depression trials after psychosis events

Overview

Updated 2 hours ago

Xenon Pharmaceuticals stopped enrolling new patients in its Phase 3 depression and bipolar disorder trials on September 17 after participants reported neuropsychiatric side effects, including a small number of psychosis cases. The company's stock fell more than 25% the next day.

The same day, Xenon submitted a New Drug Application to the FDA for azetukalner to treat focal seizures in epilepsy. The psychiatry program was Xenon's bet on moving beyond epilepsy into the far larger depression market, built on a promising Phase 2 result.

Why it matters

The pause threatens Xenon's expansion beyond epilepsy into the larger depression market, built on a single Phase 2 result.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

~360

Patients enrolled in X-NOVA2

Enrollment closed at roughly 80% of the 450-patient target after the pause.

>25%

One-day stock drop

Xenon shares plunged over 25% on September 18, hitting a six-month low.

~1%

Psychosis event rate

Rate of psychosis cases in the psychiatry trials, per Chief Medical Officer Christopher Kenney.

1,500+

Patient-years of epilepsy exposure

Cumulative azetukalner exposure in epilepsy trials, the company's safety benchmark.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Ian Mortimer

Chief Executive Officer, Xenon Pharmaceuticals

Leading the company through the NDA submission and psychiatry trial pause

Christopher Kenney

Chief Medical Officer, Xenon Pharmaceuticals

Explained the safety data behind the enrollment pause

Organizations Involved

Xenon Pharmaceuticals

Biopharmaceutical company

Developer of azetukalner; paused psychiatry trial enrollment pending dosing changes

Vancouver-area biopharmaceutical company developing azetukalner, a Kv7 potassium channel modulator, for epilepsy and psychiatric disorders.

U.S. Food and Drug Administration

Federal regulatory agency

Reviewing azetukalner New Drug Application for focal seizures

The U.S. agency responsible for reviewing new drug applications and monitoring drug safety.

Data Safety Monitoring Board (DSMB)

Independent safety oversight committee

Consulted on the enrollment pause decision

An independent group of experts that monitors trial safety data and advises sponsors on whether to continue, modify, or halt studies.

Timeline

March 2026 September 2026

3 events Latest: Today

September 2026
Xenon stock plunges over 25%
Today Market reaction

Shares fall to a six-month low as investors weigh the psychiatry setback against the epilepsy filing.
Today
Xenon submits NDA, pauses psychiatry trials
Regulatory

Files NDA for focal seizures and pauses psychiatry trial enrollment after adverse events.
Yesterday
March 2026
Xenon stock jumps 50% after positive azetukalner results
Market reaction

Investors bid shares up 50% after positive late-stage results for the epilepsy program.
March 9th, 2026

Scenarios

Xenon resumes psychiatry enrollment with modified dosing

Likely Resolves by Q2 2027

Discussed by: Company executives, who called the pause precautionary and temporary

Xenon evaluates dose-escalation regimens in consultation with the DSMB, modifies the MDD and BPD study protocols, and resumes enrolling new patients within several months. X-NOVA2 data still arrives in Q1 2027. The episode becomes a footnote if modified dosing holds efficacy while reducing neuropsychiatric events.

X-NOVA2 misses its primary endpoint, psychiatry program in question

Possible Resolves by Q1 2027

Discussed by: Bears following the stock; the company has said the study is powered to show a 2.5-point separation

When topline data arrive in Q1 2027, X-NOVA2 shows a placebo-corrected HAM-D17 improvement below the 2.5-point threshold the company considers clinically meaningful. Combined with the safety signal, the result undermines the case for continuing the psychiatry program, and Xenon pivots fully to epilepsy.

Xenon discontinues the psychiatry program outright

Unlikely Resolves by Q2 2027

Discussed by: The bear case; would follow if dosing changes fail or X-NOVA2 data disappoint

If neuropsychiatric events persist even with modified dosing, or if the FDA raises concerns that affect the epilepsy NDA review, Xenon terminates the MDD and BPD studies. The company focuses resources on the epilepsy franchise, where azetukalner is already a strong commercial prospect.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2004-2007

FDA antidepressant suicidality warnings (2004-2007)

FDA added boxed warnings on antidepressants about increased suicidality risk in children (2004) and young adults up to 25 (2007), after pooled analyses of clinical trials showed elevated rates relative to placebo. Prescriptions for antidepressants in youth dropped sharply.

Then

Warnings were added to all SSRIs and related drugs, with prescriber guides and monitoring requirements.

Now

Later research suggested the risk is age-dependent and benefit-risk in adults is favorable. The episode showed how difficult it is to attribute psychiatric events in trials where the disease itself produces those symptoms.

Why this matters now

In depression and bipolar trials, psychosis and suicidal ideation are also disease features, making it hard to distinguish drug effects from the underlying illness. This interpretive challenge now faces Xenon and the FDA.

2007-2016

Chantix boxed warning and removal (2007-2016)

Pfizer's varenicline (Chantix) launched in 2006 as a smoking-cessation drug. Post-marketing reports of suicidal thoughts and depression led the FDA to add a boxed warning in 2009. A large 2016 study (EAGLES, 8,000 patients) found psychiatric event rates similar to placebo, and FDA removed the boxed warning that year.

Then

Chantix sales fell and the drug faced liability claims.

Now

The EAGLES data restored confidence; varenicline remains a standard smoking-cessation treatment.

Why this matters now

Shows that psychiatric side effect signals in a central nervous system drug can be contextualized with rigorous trial data. Early reports looked alarming; the drug proved safe relative to alternatives.

March 2019

Spravato (esketamine) approval with REMS (2019)

Janssen's esketamine nasal spray for treatment-resistant depression won FDA approval in March 2019 despite dissociative side effects, sedation, and abuse potential. The agency required a Risk Evaluation and Mitigation Strategy (REMS) mandating supervised administration at certified healthcare facilities.

Then

Patients must be observed for at least two hours after each dose in a certified clinic.

Now

Spravato became a commercial success, demonstrating that drugs with significant psychiatric adverse events can reach the market when the unmet medical need is high.

Why this matters now

Provides a realistic path for azetukalner's psychiatry program even if neuropsychiatric events persist: a risk mitigation program and careful dosing could still support approval.